Literature DB >> 29317254

Revisiting progesterone receptor (PR) actions in breast cancer: Insights into PR repressive functions.

Cecilia J Proietti1, Mauro E Cenciarini2, Patricia V Elizalde2.   

Abstract

Progesterone receptor (PR) is a master regulator in female reproductive tissues that controls developmental processes and proliferation and differentiation during the reproductive cycle and pregnancy. PR also plays a role in progression of endocrine-dependent breast cancer. As a member of the nuclear receptor family of ligand-dependent transcription factors, the main action of PR is to regulate networks of target gene expression in response to binding its cognate steroid hormone, progesterone. Liganded-PR transcriptional activation has been thoroughly studied and associated mechanisms have been described while progesterone-mediated repression has remained less explored. The present work summarizes recent advances in the understanding of how PR-mediated repression is accomplished in breast cancer cells and highlights the significance of fully understanding the determinants of context-dependent PR action.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Progesterone receptor; Repressive actions

Mesh:

Substances:

Year:  2018        PMID: 29317254     DOI: 10.1016/j.steroids.2017.12.015

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  4 in total

1.  Characterisation of progestins used in hormonal contraception and progesterone via the progesterone receptor.

Authors:  Kim Enfield; Meghan Cartwright; Renate Louw-du Toit; Chanel Avenant; Donita Africander; Janet P Hapgood
Journal:  Biochem Biophys Res Commun       Date:  2020-09-29       Impact factor: 3.575

2.  Is 18F-FDG PET/CT Beneficial for Newly Diagnosed Breast Cancer Patients With Low Proportion of ER Expression?

Authors:  Jiachen Liu; Runlu Sun; Yuping Yin; Jingyan Li; Xuming Liu; Sheng Liu; Zhanlei Zhang; Jieting Hu; Xiaoting Wan; Hong Zhang
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

3.  Impact of 6 month conjugated equine estrogen versus estradiol-treatment on biomarkers and enriched gene sets in healthy mammary tissue of non-human primates.

Authors:  Gabriel Hobi; J Mark Cline; Kelly F Ethun; Cedric Simillion; Irene Keller; Petra Stute
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

4.  Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer.

Authors:  Yiyang Li; Wei Zhou; Xiangbing Meng; Sarina D Murray; Long Li; Abby Fronk; Vanessa J Lazaro-Camp; Kuo-Kuang Wen; Meng Wu; Adam Dupuy; Kimberly K Leslie; Shujie Yang
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.